Ruxolitinib

Ruxolitinib, sold under the brand names Jakafi, Jakavi, and Opzelura is a medication used for the treatment of intermediate or high-risk myelofibrosis,a type of myeloproliferative disorder that affects the bone marrow; polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea;and steroid-refractory acute graft-versus-host disease.Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi,and by Novartis elsewhere in the world, under the brand name Jakavi

A Anant Labs fabrica e fornece impurezas de Ruxolitinib de alta qualidade para o mercado global. Nossas impurezas EP de Ruxolitinib são utilizadas por fabricantes de APIs e empresas farmacêuticas totalmente integradas em todo o mundo.